MedTrace Logo

Remimazolam NeuroImaging

NCT07290205 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-02

No results posted yet for this study

Summary

This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task

Conditions

  • Anesthesia
  • Pain
  • Remimazolam

Interventions

DRUG

Remimazolam

Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.

DEVICE

Peripheral Nerve Stimulation

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Keith M Vogt

    lead OTHER

Principal Investigators

  • Keith M Vogt, MD, PhD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-27
Primary Completion
2027-12-01
Completion
2027-12-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07290205 on ClinicalTrials.gov